Dopamine D1 receptor availability in Gilles de la Tourette syndrome (GTS): A C-11-SCH23390 PET study

Ziel/Aim Clinically, the GTS is mainly characterized by motor and vocal tics. Current treatment strategies are often unsatisfactory. This provokes the need for further elucidation of the underlying pathophysiology. Literature suggests a dysregulated dopaminergic system, with promising treatment results for the selective dopamine D1 receptor (D1R) antagonist ecopipam. So far, D1Rs have not been investigated in vivo in GTS. We hypothesize that GTS patients have a reduced D1R availability that correlates with clinical disease severity.